脾多肽联合多西他赛及顺铂治疗中老年晚期非小细胞肺癌疗效观察  

Observation of efficacy of spleen polypeptide and docetaxel plus cisplation in treatment of elderly patients with advanced non-small cell lung cancer

作　　者：尚立群[1] 苗毅[1] 张永庆[1] 陈瑞琳[1] 杨淑梅[1] 

机构地区：[1]陕西省人民医院呼吸内科,陕西西安710068

出　　处：《现代肿瘤医学》2017年第15期2412-2415,共4页Journal of Modern Oncology

基　　金：西安市科技计划项目[编号:2016047SF/YX03(4)]

摘　　要：目的:观察脾多肽对多西他赛联合顺铂治疗中晚期非小细胞肺癌(NSCLC)的疗效和不良反应。方法:将60例NSCLC患者随机分为两组:脾多肽组(30例):脾多肽联合多西他赛+顺铂;对照组(30例):单用多西他赛+顺铂。脾多肽组于开始联合化疗方案时即给予脾多肽6 ml/d,静脉滴注,连续应用2周。分别于化疗前后对患者血常规(包括外周血白细胞,血小板,血红蛋白),肝肾功能,消化道反应,免疫功能,生存评分,疗效进行评价。结果:脾多肽组及对照组的总有效率分别是46.7%和43.3%。治疗后,脾多肽组的白细胞、红细胞、血红蛋白、血小板较治疗前的下降程度均比对照组低;治疗后,脾多肽组免疫指标:NK细胞、T细胞、CD4阳性细胞百分率及CD4/CD8比值均较治疗前和对照组明显增加。结论:脾多肽联合多西他赛+顺铂治疗晚期非小细胞肺癌可以增加疗效,减轻骨髓毒性,提高机体免疫力,提高患者生存质量和化疗耐受性值得临床推广。Objective： To observation of efficacy and toxicity of spleen polypeptide and docetaxel plus cisplation in treatment of advanced non-small cell lung cancer（ NSCLC）. Methods： The 60 cases of NSCLC patients were randomly into 2 groups,which were spleen peptide group（ 30 cases） and control group（ 30 cases）. The spleen peptide group was given spleen peptide jointly with docetaxel plus cisplation and the control group with docetaxel plus cisplation. The spleen peptide group was treated with the spleen peptide 6mg/d intravenously from the beginning of combination therapy,1 week. The patients were detected with blood（ including peripheral blood leukocytes,platelets,hemoglobin）,liver and kidney function,gastrointestinal reactions,immune functions testing in order to survive score and treatment evaluation before and after chemotheraphy. Results： The total effective rate were 46. 7% and 43. 3% in the spleen peptide group and the control group respectively. The degree of reduction of white blood cells,platelets and hemoglobin in the spleen peptide group was better than that in the control group. The percentage of positive cells of immune parameters NK/T-cell CD4 positive cell and CD4/CD8 ratio were increase significantly. Conclusion： Spleen peptides combined with docetaxel plus cisplation may increase efficacy,reduce bone marrow toxicity,improve immunity,improve the quality of life and tolerability of chemotherapy in patients with advanced non-small cell lung cancer.The therapy was worthy of promotion.

关 键 词：脾多肽 非小细胞肺癌 多西他赛 顺铂 联合化疗 

分 类 号：R734.2[医药卫生—肿瘤]